Recent Company News

• 08:38 AM ET May 18, 2026
  

  CSPC Pharmaceutical Group receives NMPA trial approval for SYH2095

• 05:48 AM ET May 11, 2026
  

  NMPA grants breakthrough therapy designation to CSPC Pharmaceutical Group's SYS6010 (HK$8.20, 0.00)

• 09:36 PM ET May 05, 2026
  

  StreetAccount Sector Summary - China Healthcare April Recap

• 07:23 AM ET Apr 29, 2026
  

  CSPC Pharmaceutical Group receives marketing authorization approval for Amphotericin B Liposomal, Powder for Concentrate for Dispersion for Infusion (HK$8.36, 0.00)

• 07:19 AM ET Apr 29, 2026
  

  CSPC Pharmaceutical Group receives IND approval to conduct clinical trials in US for SYS6051 (HK$8.36, 0.00)

• 07:53 AM ET Apr 28, 2026
  

  CSPC Pharmaceutical Group releases sustainability report (HK$8.41, 0.00)

• 12:04 PM ET Apr 24, 2026
  

  FDA grants orphan drug designation to CSPC for the treatment of small cell lung cancer (HK$8.98, 0.00)

• 07:49 AM ET Apr 24, 2026
  

  CSPC Pharmaceutical receives FDA approval to conduct clinical trials of SYH2095 in the US (HK$8.98, 0.00)

• 05:57 AM ET Apr 20, 2026
  

  CSPC Pharmaceutical Group phae IIb/III clinical study of HB1901 for PEComa meets primary endpoint (HK$9.01, 0.00)

• 05:38 AM ET Apr 15, 2026
  

  CSPC Pharmaceutical Group obtains clinical trial approval for SYS6051 for advanced solid tumors (HK$9.44, 0.00)